Mucuna Pruriens Therapy in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

September 30, 2016

Conditions
Parkinson's Disease
Interventions
OTHER

MP-Equivalent

Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.

OTHER

MP-Low

Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI

OTHER

MP+DDCI

Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.

DRUG

LD+DDCI

Levodopa plus Benserazide

DRUG

LD-DDCI

Levodopa without any DDCI

OTHER

Placebo

Groundnuts powder

Trial Locations (1)

Unknown

Clinica Niño Jesus, Santa Cruz de la Sierra

All Listed Sponsors
collaborator

Grisons Foundation for Parkinson's Disease

OTHER

lead

ASST Gaetano Pini-CTO

OTHER

NCT02680977 - Mucuna Pruriens Therapy in Parkinson's Disease | Biotech Hunter | Biotech Hunter